Statins and heart plaque changes in people with melanoma on immunotherapy
Part of Cancer, Heart & circulation, Skin clinical trials.
This trial studies whether taking a cholesterol medicine called a statin can slow the buildup or worsening of coronary artery plaque in people with melanoma who are receiving checkpoint inhibitor (immunotherapy) treatment. It mainly looks at heart scans over time to see if statins change the progression of coronary atherosclerosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years old or older and can give informed consent and follow study instructions.
- You have melanoma (confirmed by pathology) and are planning to start, are on, or recently finished checkpoint inhibitor immunotherapy.
- You can get high-quality heart imaging for the study, and your doctor believes you can return for follow-up scans (CTCA).
- You do NOT have known cardiovascular disease that has already caused symptoms (clinically manifest heart disease).
- You do not have severe kidney or liver problems (kidney filtering is too low, or you have severe liver disease/cirrhosis).
- You are not pregnant, breastfeeding, or planning pregnancy during the study. (If female, you must be able to avoid pregnancy.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the statin drug atorvastatin can prevent immunotherapy from worsening artery plaque in people with melanoma. It aims to lower the risk of heart problems caused by treatment.
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This study looks at heart health in people who have finished immunotherapy for melanoma. It uses MRI scans to check for any heart problems that may have developed after treatment.
This trial tests whether higher doses of cholesterol-lowering medication (statins) can slow down plaque buildup in the heart arteries of younger and middle-aged adults with stable chest pain. It may help prevent heart attacks and the need for procedures like stents.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.